Biotechnology

HCE will utilize its resources in a similar manner as that employed within the biotechnology segment. In many instances pharmaceutical firms are seeking additional business opportunities within specified disease states in biologicals due to pipeline limitations.

Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842 billion during the 2019-2024 time period. This is triple the CAGR seen for 2010-2019 and is driven by an increase in regulatory approvals for novel drugs and growth in the oncology therapies and orphan drugs markets.

These situations can become opportunities for firms willing to embrace the notion that outsourced R&D to R&D

pipelines and will be a viable option to replace revenues being compromised by increased competition due to patent expiry and or end of product life cycle limitations. Certain disease states such as cancer, obesity, diabetes, neurology and infectious disease are attractive markets that HCE can assist firms willing to enter such markets.